Thesis pillars
- Best In Class Margins Valuation→Stable
- Weak Growth Falling Estimates→Stable
- Price Above Analyst Target↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026
InMode Ltd. (INMD) Stock Analysis
Falling Knife setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $12.42 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth.
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.... Read more
Sell if holding. Analyst target reached at $12.42 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Score 5.5/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated Nov 21, 2026Recent Developments — InMode Ltd.
Latest news
- NEWS M.N. Business Strategy, Ltd. Cancels Acquisition of Remaining InMode Ltd. Shares — fiscal.ai Nov 21, 2026 neutral
- NEWS InMode Reports Q4 Earnings Miss — fiscal.ai Nov 17, 2026 negative
- NEWS InMode Announces Bangkok as Host for 2026 Global Summit — fiscal.ai Nov 17, 2026 neutral
- NEWS Baird Maintains InMode Hold Rating and Lowers Price Target — fiscal.ai Nov 15, 2026 negative
- NEWS Baird Maintains Neutral on InMode, Lowers Price Target to $15 — benzinga Nov 12, 2026 negative
Latest item Nov 21, 2026 · Generated 2026-11-22T11:52:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Revenue shrinking — -1.1% YoY. Growth thesis broken unless recovery story develops.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $12.42 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Prior stop was $12.03. Score 5.5/10, moderate confidence.
Analyst target: $12.47 (+0.4% upside). Prior stop was $12.03. Stop-loss: $12.03.
Analyst target reached - limited upside remaining; Weak growth; Negative momentum.
InMode Ltd. trades at a P/E of 10.4 (forward 9.1). TrendMatrix value score: 8.4/10. Verdict: Sell.
10 analysts rate INMD, with a consensus score of 2.5/5. 3 analysts publish price targets averaging $15.
What does InMode Ltd. do?InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its...
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.